The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Awiqli insulin icodec | Novo Nordisk A/S | Diabetes Mellitus; Diabetes Mellitus, Type 2 | 🇪🇺 EU 2024-05-17 | Order → |
| Fabhalta iptacopan OrphanPRIMEAdditional monitoring | Novartis Europharm Limited | Hemoglobinuria, Paroxysmal | 🇪🇺 EU 2024-05-17 | Order → |
| Wyost denosumab BiosimilarAdditional monitoring | Sandoz GmbH | Giant Cell Tumor of Bone; Neoplasms, Bone Tissue | 🇪🇺 EU 2024-05-17 | Order → |
| Jubbonti denosumab BiosimilarAdditional monitoring | Sandoz GmbH | Osteoporosis; Osteoporosis, Postmenopausal; Bone Resorption | 🇪🇺 EU 2024-05-16 | Order → |
| Omlyclo omalizumab BiosimilarAdditional monitoring | Celltrion Healthcare Hungary Kft. | Asthma; Urticaria | 🇪🇺 EU 2024-05-16 | Order → |
| Dimethyl fumarate Accord dimethyl fumarate Generic | Accord Healthcare Ltd | Multiple Sclerosis | 🇪🇺 EU 2024-04-22 | Order → |
| Dimethyl fumarate Mylan dimethyl fumarate Generic | Mylan Pharmaceuticals Limited | Multiple Sclerosis | 🇪🇺 EU 2024-04-22 | Order → |
| Dimethyl fumarate Neuraxpharm dimethyl fumarate Generic | Neuraxpharm Pharmaceuticals S.L. | Multiple Sclerosis | 🇪🇺 EU 2024-04-22 | Order → |
| Emblaveo aztreonam;avibactam | Pfizer Europe MA EEIG | Gram-Negative Bacterial Infections; Urinary Tract Infections; Healthcare-Associated Pneumonia; Soft Tissue Infections | 🇪🇺 EU 2024-04-22 | Order → |
| Apremilast Accord apremilast Generic | Accord Healthcare S.L.U. | Arthritis, Psoriatic; Psoriasis; Behcet Syndrome; Oral Ulcer | 🇪🇺 EU 2024-04-19 | Order → |
| Celldemic zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) Additional monitoring | Seqirus Netherlands B.V. | Influenza, Human | 🇪🇺 EU 2024-04-19 | Order → |
| Filspari sparsentan OrphanAdditional monitoring | Vifor France | Glomerulonephritis, IGA | 🇪🇺 EU 2024-04-19 | Order → |
| Incellipan pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) ConditionalAdditional monitoring | Seqirus Netherlands B.V. | Influenza, Human | 🇪🇺 EU 2024-04-19 | Order → |
| Nintedanib Accord nintedanib Generic | Accord Healthcare S.L.U. | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Scleroderma, Systemic; Pulmonary Fibrosis | 🇪🇺 EU 2024-04-19 | Order → |
| Pyzchiva ustekinumab BiosimilarAdditional monitoring | Samsung Bioepis NL B.V. | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic | 🇪🇺 EU 2024-04-19 | Order → |
| Tizveni tislelizumab Additional monitoring | BeiGene Ireland Ltd | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2024-04-19 | Order → |
| Voydeya danicopan OrphanPRIMEAdditional monitoring | Alexion Europe SAS | Hemoglobinuria, Paroxysmal; Hemolysis | 🇪🇺 EU 2024-04-19 | Order → |
| Zynyz retifanlimab OrphanAdditional monitoring | Incyte Biosciences Distribution B.V. | Carcinoma, Merkel Cell | 🇪🇺 EU 2024-04-19 | Order → |
| Niapelf paliperidone Generic | Neuraxpharm Pharmaceuticals S.L. | Schizophrenia | 🇪🇺 EU 2024-03-31 | Order → |
| Exblifep cefepime;enmetazobactam Additional monitoring | Advanz Pharma Limited | Urinary Tract Infections; Pyelonephritis; Healthcare-Associated Pneumonia; Pneumonia, Ventilator-Associated | 🇪🇺 EU 2024-03-21 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.